The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases

Clinical Science

Volumn 128, Issue 12, 2015, Pages 839-861

  Maessen, Dionne E M ^a   Stehouwer, Coen D A ^a   Schalkwijk, Casper G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Advanced glycation endproducts; Ageing; Glyoxalase; Methylglyoxal; Obesity; Type 2 diabetes mellitus

Indexed keywords

ALAGEBRIUM; ALDEHYDE DEHYDROGENASE; ALDEHYDE REDUCTASE; AMINOGUANIDINE; BENFOTIAMINE; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3; GLYCOSYLATED PROTEIN; GLYOXALASE; HEAT SHOCK PROTEIN 27; HYDROXYACYLGLUTATHIONE HYDROLASE; INSULIN; KETONE BODY; LACTIC ACID; LACTOYLGLUTATHIONE LYASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; METFORMIN; METHYLGLYOXAL; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEASOME; PYRIDOXAMINE; STAT3 PROTEIN; SUPEROXIDE; THIOESTER; THREONINE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; VASCULAR CELL ADHESION MOLECULE 1; ADVANCED GLYCATION END PRODUCT; DNA; SCAVENGER;

AGING; ALZHEIMER DISEASE; ANXIETY DISORDER; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIASTOLIC DYSFUNCTION; DNA MODIFICATION; ENDOTHELIAL DYSFUNCTION; EPIGENETICS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID PEROXIDATION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; REVIEW; SCHIZOPHRENIA; DIABETIC ANGIOPATHY; METABOLISM; PHYSIOLOGY;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DNA; FREE RADICAL SCAVENGERS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LACTOYLGLUTATHIONE LYASE; NEOPLASMS; PYRUVALDEHYDE;

EID: 84929942019     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20140683     Document Type: Review

References (295)

1. Singh, R., Barden, A., Mori, T. and Beilin, L. (2001) Advanced glycation end-products: a review. Diabetologia 44, 129-146
2. Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820
3. Westwood, M.E. and Thornalley, P.J. (1995) Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. J. Protein Chem. 14, 359-372
4. Phillips, S.A. and Thornalley, P.J. (1993) The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur. J. Biochem. 212, 101-105
5. Ahmed, N., Thornalley, P.J., Dawczynski, J., Franke, S., Strobel, J., Stein, G. and Haik, G.M. (2003) Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. Invest. Ophthalmol. Vis. Sci. 44, 5287-5292
6. Matafome, P., Sena, C. and Seica, R. (2013) Methylglyoxal, obesity, and diabetes. Endocrine 43, 472-484
7. Hanssen, N.M., Stehouwer, C.D. and Schalkwijk, C.G. (2014) Methylglyoxal and glyoxalase I in atherosclerosis. Biochem. Soc. Trans. 42, 443-449
8. Thornalley, P.J. and Rabbani, N. (2011) Glyoxalase in tumourigenesis and multidrug resistance. Semin. Cell Dev. Biol. 22, 318-325
9. Srikanth, V., Westcott, B., Forbes, J., Phan, T.G., Beare, R., Venn, A., Pearson, S., Greenaway, T., Parameswaran, V. and Münch, G. (2013) Methylglyoxal, cognitive function and cerebral atrophy in older people. J. Gerontol. A Biol. Sci. Med. Sci. 68, 68-73
10. Sousa Silva, M., Gomes, R.A., Ferreira, A.E., Ponces, Freire, A. and Cordeiro, C. (2013) The glyoxalase pathway: the first hundred years. and beyond. Biochem. J. 453, 1-15
11. Kalapos, M.P. (1999) Methylglyoxal in living organisms: chemistry, biochemistry, toxicology and biological implications. Toxicol. Lett. 110, 145-175
12. Thornalley, P.J. (1988) Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem. J. 254, 751-755
13. Thornalley, P.J., Langborg, A. and Minhas, H.S. (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344 (Pt 1), 109-116
14. Reichard, Jr, G.A., Skutches, C.L., Hoeldtke, R.D. and Owen, O.E. (1986) Acetone metabolism in humans during diabetic ketoacidosis. Diabetes 35, 668-674
15. Lyles, G.A. and Chalmers, J. (1992) The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem. Pharmacol. 43, 1409-1414
16. Baynes, J.W. and Thorpe, S.R. (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 28, 1708-1716
17. Rabbani, N. and Thornalley, P.J. (2014) Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. Nat. Protoc. 9, 1969-1979
18. Kalapos, M.P. (2013) Where does plasma methylglyoxal originate from Diabetes Res. Clin. Pract. 99, 260-271
19. Degen, J., Hellwig, M. and Henle, T. (2012) 1, 2-dicarbonyl compounds in commonly consumed foods. J. Agric. Food Chem. 60, 7071-7079
20. Beisswenger, P.J., Howell, S.K., Touchette, A.D., Lal, S. and Szwergold, B.S. (1999) Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48, 198-202
21. Lapolla, A., Flamini, R., Lupo, A., Arico, N.C., Rugiu, C., Reitano, R., Tubaro, M., Ragazzi, E., Seraglia, R. and Traldi, P. (2005) Evaluation of glyoxal and methylglyoxal levels in uremic patients under peritoneal dialysis. Ann. N. Y. Acad. Sci. 1043, 217-224
22. Scheijen, J.L. and Schalkwijk, C.G. (2014) Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen. Clin. Chem. Lab. Med. 52, 85-91
23. Beisswenger, P., Heine, R.J., Leiter, L.A., Moses, A. and Tuomilehto, J. (2004) Prandial glucose regulation in the glucose triad: emerging evidence and insights. Endocrine 25, 195-202
24. Nakayama, K., Nakayama, M., Iwabuchi, M., Terawaki, H., Sato, T., Kohno, M. and Ito, S. (2008) Plasma alpha-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients. Am. J. Nephrol. 28, 871-878
25. Lu, J., Randell, E., Han, Y., Adeli, K., Krahn, J. and Meng, Q.H. (2011) Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. Clin. Biochem. 44, 307-311
26. Phillips, S.A., Mirrlees, D. and Thornalley, P.J. (1993) Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. Biochem. Pharmacol. 46, 805-811
27. Dobler, D., Ahmed, N., Song, L., Eboigbodin, K.E. and Thornalley, P.J. (2006) Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 55, 1961-1969
28. Rabbani, N. and Thornalley, P.J. (2011) Glyoxalase in diabetes, obesity and related disorders. Semin. Cell Dev. Biol. 22, 309-317
29. Rabbani, N. and Thornalley, P.J. (2014) Dicarbonyl proteome and genome damage in metabolic and vascular disease. Biochem. Soc. Trans. 42, 425-432
30. Izaguirre, G., Kikonyogo, A. and Pietruszko, R. (1998) Methylglyoxal as substrate and inhibitor of human aldehyde dehydrogenase: comparison of kinetic properties among the three isozymes. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 119, 747-754
31. Rabbani, N. and Thornalley, P.J. (2012) Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids 42, 1133-1142
32. Baba, S.P., Barski, O.A., Ahmed, Y., O'Toole, T.E., Conklin, D.J., Bhatnagar, A. and Srivastava, S. (2009) Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue. Diabetes 58, 2486-2497
33. Lo, T.W., Westwood, M.E., McLellan, A.C., Selwood, T. and Thornalley, P.J. (1994) Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N-alpha-acetylarginine, N-alpha-acetylcysteine, and N-alpha-acetyllysine, and bovine serum albumin. J. Biol. Chem. 269, 32299-32305
34. Thornalley, P.J., Battah, S., Ahmed, N., Karachalias, N., Agalou, S., Babaei-Jadidi, R. and Dawnay, A. (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375, 581-592
35. Ahmed, N. and Thornalley, P.J. (2005) Peptide mapping of human serum albumin modified minimally by methylglyoxal in vitro and in vivo. Ann. N. Y. Acad. Sci. 1043, 260-266
36. Watanabe, H., Tanase, S., Nakajou, K., Maruyama, T., Kragh-Hansen, U. and Otagiri, M. (2000) Role of arg-410 and tyr-411 in human serum albumin for ligand binding and esterase-like activity. Biochem. J. 349 (Pt 3), 813-819
37. Faure, P., Troncy, L., Lecomte, M., Wiernsperger, N., Lagarde, M., Ruggiero, D. and Halimi, S. (2005) Albumin antioxidant capacity is modified by methylglyoxal. Diabetes Metab. 31, 169-177
38. Abordo, E.A. and Thornalley, P.J. (1997) Synthesis and secretion of tumour necrosis factor-alpha by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunol. Lett. 58, 139-147
39. Westwood, M.E., McLellan, A.C. and Thornalley, P.J. (1994) Receptor-mediated endocytic uptake of methylglyoxal-modified serum albumin. Competition with advanced glycation end product-modified serum albumin at the advanced glycation end product receptor. J. Biol. Chem. 269, 32293-32298
40. Fan, X., Subramaniam, R., Weiss, M.F. and Monnier, V.M. (2003) Methylglyoxal-bovine serum albumin stimulates tumor necrosis factor alpha secretion in RAW 264.7 cells through activation of mitogen-activating protein kinase, nuclear factor kappaB and intracellular reactive oxygen species formation. Arch. Biochem. Biophys. 409, 274-286
41. Westwood, M.E. and Thornalley, P.J. (1996) Induction of synthesis and secretion of interleukin 1 beta in the human monocytic THP-1 cells by human serum albumins modified with methylglyoxal and advanced glycation endproducts. Immunol. Lett. 50, 17-21
42. Westwood, M.E., Argirov, O.K., Abordo, E.A. and Thornalley, P.J. (1997) Methylglyoxal-modified arginine residues - a signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells. Biochim. Biophys. Acta 1356, 84-94
43. Monnier, V.M., Sell, D.R., Strauch, C., Sun, W., Lachin, J.M., Cleary, P.A. and Genuth, S. (2013) The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. J. Diabetes Complications 27, 141-149
44. Bose, T., Bhattacherjee, A., Banerjee, S. and Chakraborti, A.S. (2013) Methylglyoxal-induced modifications of hemoglobin: structural and functional characteristics. Arch. Biochem. Biophys. 529, 99-104
45. Morcos, M., Du, X., Pfisterer, F., Hutter, H., Sayed, A.A., Thornalley, P., Ahmed, N., Baynes, J., Thorpe, S., Kukudov, G. et al. (2008) Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell 7, 260-269
46. Queisser, M.A., Yao, D., Geisler, S., Hammes, H.P., Lochnit, G., Schleicher, E.D., Brownlee, M. and Preissner, K.T. (2010) Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes 59, 670-678
47. Nagaraj, R.H., Panda, A.K., Shanthakumar, S., Santhoshkumar, P., Pasupuleti, N., Wang, B. and Biswas, A. (2012) Hydroimidazolone modification of the conserved Arg12 in small heat shock proteins: studies on the structure and chaperone function using mutant mimics. PloS ONE 7, e30257
48. Xue, J., Ray, R., Singer, D., Bohme, D., Burz, D.S., Rai, V., Hoffmann, R. and Shekhtman, A. (2014) The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry 53, 3327-3335
49. Shipanova, I.N., Glomb, M.A. and Nagaraj, R.H. (1997) Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Arch. Biochem. Biophys. 344, 29-36
50. Oya, T., Hattori, N., Mizuno, Y., Miyata, S., Maeda, S., Osawa, T. and Uchida, K. (1999) Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J. Biol. Chem. 274, 18492-18502
51. Oya-Ito, T., Liu, B.F. and Nagaraj, R.H. (2006) Effect of methylglyoxal modification and phosphorylation on the chaperone and anti-apoptotic properties of heat shock protein J. Cell Biochem. 99, 279-291
52. Nagaraj, R.H., Oya-Ito, T., Padayatti, P.S., Kumar, R., Mehta, S., West, K., Levison, B., Sun, J., Crabb, J.W. and Padival, A.K. (2003) Enhancement of chaperone function of alpha-crystallin by methylglyoxal modification. Biochemistry 42, 10746-10755
53. Schalkwijk, C.G., van Bezu, J., van der Schors, R.C., Uchida, K., Stehouwer, C.D. and van Hinsbergh, V.W. (2006) Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells. FEBS Lett. 580, 1565-1570
54. Nagaraj, R.H., Oya-Ito, T., Padayatti, P.S., Kumar, R., Mehta, S., West, K., Levison, B., Sun, J., Crabb, J.W. and Padival, A.K. (2003) Enhancement of chaperone function of alpha-crystallin by methylglyoxal modification. Biochemistry 42, 10746-10755
55. Schalkwijk, C.G., van Bezu, J., van der Schors, R.C., Uchida, K., Stehouwer, C.D. and van Hinsbergh, V.W. (2006) Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells. FEBS Lett. 580, 1565-1570
56. Gawlowski, T., Stratmann, B., Stork, I., Engelbrecht, B., Brodehl, A., Niehaus, K., Korfer, R., Tschoepe, D. and Milting, H. (2009) Heat shock protein 27 modification is increased in the human diabetic failing heart. Horm. Metab. Res. 41, 594-599
57. van Eupen, M.G., Schram, M.T., Colhoun, H.M., Hanssen, N.M., Niessen, H.W., Tarnow, L., Parving, H.H., Rossing, P., Stehouwer, C.D. and Schalkwijk, C.G. (2013) The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. Diabetologia 56, 1845-1855
58. Ahmed, M.U., Brinkmann Frye, E., Degenhardt, T.P., Thorpe, S.R. and Baynes, J.W. (1997) N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem. J. 324 (Pt 2), 565-570
59. Frye, E.B., Degenhardt, T.P., Thorpe, S.R. and Baynes, J.W. (1998) Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J. Biol. Chem. 273, 18714-18719
60. Lederer, M.O. and Klaiber, R.G. (1999) Cross-linking of proteins by Maillard processes: characterization and detection of lysine-arginine cross-links derived from glyoxal and methylglyoxal. Bioorg. Med. Chem. 7, 2499-2507
61. 2-carboxyethyl-2'-deoxyguanosine. Chem. Res. Toxicol. 17, 1385-1390
62. 2-(1-Carboxyethyl)-2'-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Chem. Res. Toxicol. 21, 2148-2155
63. Thornalley, P.J., Waris, S., Fleming, T., Santarius, T., Larkin, S.J., Winklhofer-Roob, B.M., Stratton, M.R. and Rabbani, N. (2010) Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance. Nucleic Acids Res. 38, 5432-5442
64. Murata-Kamiya, N., Kamiya, H., Kaji, H. and Kasai, H. (2000) Methylglyoxal induces G:C to C:G and G:C to T:A transversions in the supF gene on a shuttle vector plasmid replicated in mammalian cells. Mutat. Res. 468, 173-182
65. Tu, C.Y., Chen, Y.F., Lii, C.K. and Wang, T.S. (2013) Methylglyoxal induces DNA crosslinks in ECV304 cells via a reactive oxygen species-independent protein carbonylation pathway. Toxicol. in Vitro 27, 1211-1219
66. Petrova, K.V., Millsap, A.D., Stec, D.F. and Rizzo, C.J. (2014) Characterization of the deoxyguanosine-lysine cross-link of methylglyoxal. Chem. Res. Toxicol. 27, 1019-1029
67. Mir, A.R., Uddin, M., Alam, K. and Ali, A. (2014) Methylglyoxal mediated conformational changes in histone H2A-generation of carboxyethylated advanced glycation end products. Int. J. Biol. Macromol. 69, 260-266
68. Vander Jagt, D.L., Daub, E., Krohn, J.A. and Han, L.P. (1975) Effects of pH and thiols on the kinetics of yeast glyoxalase I. An evaluation of the random pathway mechanism. Biochemistry 14, 3669-3675
69. Vander Jagt, D.L., Han, L.P. and Lehman, C.H. (1972) Kinetic evaluation of substrate specificity in the glyoxalase-I-catalyzed disproportionation of ketoaldehydes. Biochemistry 11, 3735-3740
70. Thornalley, P.J. (2003) Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem. Soc. Trans. 31, 1343-1348
71. Ranganathan, S., Ciaccio, P.J., Walsh, E.S. and Tew, K.D. (1999) Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene 240, 149-155
72. Birkenmeier, G., Stegemann, C., Hoffmann, R., Gunther, R., Huse, K. and Birkemeyer, C. (2010) Posttranslational modification of human glyoxalase 1 indicates redox-dependent regulation. PloS ONE 5, e10399
73. Mitsumoto, A., Kim, K.R., Oshima, G., Kunimoto, M., Okawa, K., Iwamatsu, A. and Nakagawa, Y. (1999) Glyoxalase I is a novel nitric-oxide-responsive protein. Biochem. J. 344 (Pt 3), 837-844
74. de Hemptinne, V., Rondas, D., Toepoel, M. and Vancompernolle, K. (2009) Phosphorylation on Thr-106 and NO-modification of glyoxalase I suppress the TNF-induced transcriptional activity of NF-kappaB. Mol. Cell Biochem. 325, 169-178
75. Van Herreweghe, F., Mao, J., Chaplen, F.W., Grooten, J., Gevaert, K., Vandekerckhove, J. and Vancompernolle, K. (2002) Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE. Proc. Natl. Acad. Sci. U.S.A. 99, 949-954
76. Thornalley, P.J. (1993) The glyoxalase system in health and disease. Mol. Aspects Med. 14, 287-371
77. Atkins, T.W. and Thornally, P.J. (1989) Erythrocyte glyoxalase activity in genetically obese (ob/ob) and streptozotocin diabetic mice. Diabetes Res. 11, 125-129
78. Barati, M.T., Merchant, M.L., Kain, A.B., Jevans, A.W., McLeish, K.R. and Klein, J.B. (2007) Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice. Am. J. Physiol. Renal Physiol. 293, F1157-1165
79. Hanssen, N.M., Wouters, K., Huijberts, M.S., Gijbels, M.J., Sluimer, J.C., Scheijen, J.L., Heeneman, S., Biessen, E.A., Daemen, M.J., Brownlee, M. et al. (2014) Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur. Heart J. 35, 1137-1146
80. Shafie, A., Xue, M., Thornalley, P.J. and Rabbani, N. (2014) Copy number variation of glyoxalase I. Biochem. Soc. Trans. 42, 500-503
81. Peculis, R., Konrade, I., Skapare, E., Fridmanis, D., Nikitina-Zake, L., Lejnieks, A., Pirags, V., Dambrova, M. and Klovins, J. (2013) Identification of glyoxalase 1 polymorphisms associated with enzyme activity. Gene 515, 140-143
82. Engelen, L., Ferreira, I., Brouwers, O., Henry, R.M., Dekker, J.M., Nijpels, G., Heine, R.J., van Greevenbroek, M.M., van der Kallen, C.J., Blaak, E.E. et al. (2009) Polymorphisms in glyoxalase 1 gene are not associated with vascular complications: the Hoorn and CoDAM studies. J. Hypertens. 27, 1399-1403
83. Barua, M., Jenkins, E.C., Chen, W., Kuizon, S., Pullarkat, R.K. and Junaid, M.A. (2011) Glyoxalase I polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity - implications for autism. Autism Res. 4, 262-270
84. Junaid, M.A., Kowal, D., Barua, M., Pullarkat, P.S., Sklower Brooks, S. and Pullarkat, R.K. (2004) Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am. J. Med. Genet. A 131, 11-17
85. Gabriele, S., Lombardi, F., Sacco, R., Napolioni, V., Altieri, L., Tirindelli, M.C., Gregorj, C., Bravaccio, C., Rousseau, F. and Persico, A.M. (2014) The GLO1 C332 (Ala111) allele confers autism vulnerability: Family-based genetic association and functional correlates. J. Psychiatr. Res. 59, 108-116
86. Politi, P., Minoretti, P., Falcone, C., Martinelli, V. and Emanuele, E. (2006) Association analysis of the functional Ala111Glu polymorphism of the glyoxalase I gene in panic disorder. Neurosci. Lett. 396, 163-166
87. Agar, N.S., Board, P.G. and Bell, K. (1984) Studies of erythrocyte glyoxalase II in various domestic species: discovery of glyoxalase II deficiency in the horse. Animal Blood Groups Biochem. Genet. 15, 67-70
88. Valentine, W.N., Paglia, D.E., Neerhout, R.C. and Konrad, P.N. (1970) Erythrocyte glyoxalase II deficiency with coincidental hereditary elliptocytosis. Blood 36, 797-808
89. Misra, K., Banerjee, A.B., Ray, S. and Ray, M. (1995) Glyoxalase III from Escherichia coli: a single novel enzyme for the conversion of methylglyoxal into D-lactate without reduced glutathione. Biochem. J. 305 (Pt 3), 999-1003
90. Lee, J.Y., Song, J., Kwon, K., Jang, S., Kim, C., Baek, K., Kim, J. and Park, C. (2012) Human DJ-1 and its homologs are novel glyoxalases. Human Mol. Genet. 21, 3215-3225
91. Danaei, G., Finucane, M.M., Lu, Y., Singh, G.M., Cowan, M.J., Paciorek, C.J., Lin, J.K., Farzadfar, F., Khang, Y.H., Stevens, G.A. et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378, 31-40
92. Shinohara, M., Thornalley, P.J., Giardino, I., Beisswenger, P., Thorpe, S.R., Onorato, J. and Brownlee, M. (1998) Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J. Clin. Invest. 101, 1142-1147
93. Schalkwijk, C.G. and Stehouwer, C.D. (2005) Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin. Sci. (Lond.) 109, 143-159
94. Eringa, E.C., Serne, E.H., Meijer, R.I., Schalkwijk, C.G., Houben, A.J., Stehouwer, C.D., Smulders, Y.M. and van Hinsbergh, V.W. (2013) Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes. Rev. Endocr. Metab. Disord. 14, 39-48
95. De Bock, K., Georgiadou, M. and Carmeliet, P. (2013) Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 18, 634-647
96. Abebe, W. and Mozaffari, M. (2010) Endothelial dysfunction in diabetes: potential application of circulating markers as advanced diagnostic and prognostic tools. EPMA J. 1, 32-45
97. Brouwers, O., Niessen, P.M., Haenen, G., Miyata, T., Brownlee, M., Stehouwer, C.D., De Mey, J.G. and Schalkwijk, C.G. (2010) Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 53, 989-1000
98. Berlanga, J., Cibrian, D., Guillen, I., Freyre, F., Alba, J.S., Lopez-Saura, P., Merino, N., Aldama, A., Quintela, A.M., Triana, M.E. et al. (2005) Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin. Sci. (Lond.) 109, 83-95
99. Sena, C.M., Matafome, P., Crisostomo, J., Rodrigues, L., Fernandes, R., Pereira, P. and Seica, R.M. (2012) Methylglyoxal promotes oxidative stress and endothelial dysfunction. Pharmacol. Res. 65, 497-506
100. Ahmed, U., Dobler, D., Larkin, S.J., Rabbani, N. and Thornalley, P.J. (2008) Reversal of hyperglycemia-induced angiogenesis deficit of human endothelial cells by overexpression of glyoxalase 1 in vitro. Ann. N. Y. Acad. Sci. 1126, 262-264
101. Brouwers, O., Niessen, P.M., Miyata, T., Ostergaard, J.A., Flyvbjerg, A., Peutz-Kootstra, C.J., Sieber, J., Mundel, P.H., Brownlee, M., Janssen, B.J. et al. (2014) Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia 57, 224-235
102. Miyazawa, N., Abe, M., Souma, T., Tanemoto, M., Abe, T., Nakayama, M. and Ito, S. (2010) Methylglyoxal augments intracellular oxidative stress in human aortic endothelial cells. Free Radic. Res. 44, 101-107
103. Nagaraj, R.H., Oya-Ito, T., Bhat, M. and Liu, B. (2005) Dicarbonyl stress and apoptosis of vascular cells: prevention by alphaB-crystallin. Ann. N. Y. Acad. Sci. 1043, 158-165
104. Chan, W.H. and Wu, H.J. (2008) Methylglyoxal and high glucose co-treatment induces apoptosis or necrosis in human umbilical vein endothelial cells. J. Cell Biochem. 103, 1144-1157
105. Hou, S.M., Nori, P., Fang, J.L. and Vaca, C.E. (1995) Methylglyoxal induces hprt mutation and DNA adducts in human T-lymphocytes in vitro. Environ. Mol. Mutagen 26, 286-291
106. Kang, Y., Edwards, L.G. and Thornalley, P.J. (1996) Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA G1 growth arrest and induction of apoptosis. Leuk. Res. 20, 397-405
107. Chan, W.H., Wu, H.J. and Shiao, N.H. (2007) Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. J. Cell Biochem. 100, 1056-1069
108. Du, J., Suzuki, H., Nagase, F., Akhand, A.A., Ma, X.Y., Yokoyama, T., Miyata, T. and Nakashima, I. (2001) Superoxide-mediated early oxidation and activation of ASK1 are important for initiating methylglyoxal-induced apoptosis process. Free Radic. Biol. Med. 31, 469-478
109. Okado, A., Kawasaki, Y., Hasuike, Y., Takahashi, M., Teshima, T., Fujii, J. and Taniguchi, N. (1996) Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. Biochem. Biophys. Res. Commun. 225, 219-224
110. Su, Y., Qadri, S.M., Wu, L. and Liu, L. (2013) Methylglyoxal modulates endothelial nitric oxide synthase-associated functions in EA.hy926 endothelial cells. Cardiovasc. Diabetol. 12, 134
111. Phalitakul, S., Okada, M., Hara, Y. and Yamawaki, H. (2013) Vaspin prevents methylglyoxal-induced apoptosis in human vascular endothelial cells by inhibiting reactive oxygen species generation. Acta. Physiol. (Oxf.) 209, 212-219
112. Chang, T., Wang, R. and Wu, L. (2005) Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. Free Radic. Biol. Med. 38, 286-293
113. Wang, H., Meng, Q.H., Chang, T. and Wu, L. (2006) Fructose-induced peroxynitrite production is mediated by methylglyoxal in vascular smooth muscle cells. Life Sci. 79, 2448-2454
114. Chang, T., Untereiner, A., Liu, J. and Wu, L. (2010) Interaction of methylglyoxal and hydrogen sulfide in rat vascular smooth muscle cells. Antioxid. Redox Signal. 12, 1093-1100
115. Yang, Y., Li, S., Konduru, A.S., Zhang, S., Trower, T.C., Shi, W., Cui, N., Yu, L., Wang, Y., Zhu, D. et al. (2012) Prolonged exposure to methylglyoxal causes disruption of vascular KATP channel by mRNA instability. Am. J. Physiol. Cell Physiol. 303, C1045-1054
116. Forbes, J.M. and Cooper, M.E. (2013) Mechanisms of diabetic complications. Physiol. Rev. 93, 137-188
117. Lu, J., Randell, E., Han, Y., Adeli, K., Krahn, J. and Meng, Q.H. (2011) Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. Clin. Biochem. 44, 307-311
118. Nakayama, K., Nakayama, M., Iwabuchi, M., Terawaki, H., Sato, T., Kohno, M. and Ito, S. (2008) Plasma alpha-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients. Am. J. Nephrol. 28, 871-878
119. Beisswenger, P.J., Drummond, K.S., Nelson, R.G., Howell, S.K., Szwergold, B.S. and Mauer, M. (2005) Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 54, 3274-3281
120. Beisswenger, P.J., Howell, S.K., Russell, G.B., Miller, M.E., Rich, S.S. and Mauer, M. (2013) Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care 36, 3234-3239
121. Yao, D., Taguchi, T., Matsumura, T., Pestell, R., Edelstein, D., Giardino, I., Suske, G., Rabbani, N., Thornalley, P.J., Sarthy, V.P. et al. (2007) High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J. Biol. Chem. 282, 31038-31045
122. Rosca, M.G., Monnier, V.M., Szweda, L.I. and Weiss, M.F. (2002) Alterations in renal mitochondrial respiration in response to the reactive oxoaldehyde methylglyoxal. Am. J. Physiol. Renal Physiol. 283, F52-F59
123. Geoffrion, M., Du, X., Irshad, Z., Vanderhyden, B.C., Courville, K., Sui, G., D'Agati, V.D., Ott-Braschi, S., Rabbani, N., Thornalley, P.J. et al. (2014) Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice. Physiol. Rep. 2, e12043, doi: 10.14814/phy2.12043
124. Liu, Y.-W. W., Zhu, X., Zhang, L., Lu, Q., Wang, J.-Y. Y., Zhang, F., Guo, H., Yin, J.-L. L. and Yin, X.-X. X. (2013) Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 721, 355-364
125. Giacco, F., Du, X., D'Agati, V.D., Milne, R., Sui, G., Geoffrion, M. and Brownlee, M. (2014) Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes 63, 291-299
126. Kumagai, T., Nangaku, M., Kojima, I., Nagai, R., Ingelfinger, J.R., Miyata, T., Fujita, T. and Inagi, R. (2009) Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in rats. Am. J. Physiol. Renal Physiol. 296, F912-F921
127. Bourne, R.R., Jonas, J.B., Flaxman, S.R., Keeffe, J., Leasher, J., Naidoo, K., Parodi, M.B., Pesudovs, K., Price, H., White, R.A. et al. (2014) Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. Br. J. Ophthalmol. 98, 629-638
128. Cheung, N., Mitchell, P. and Wong, T.Y. (2010) Diabetic retinopathy. Lancet 376, 124-136
129. Fosmark, D.S., Berg, J.P., Jensen, A.-B. B., Sandvik, L., Agardh, E., Agardh, C.-D. D. and Hanssen, K.F. (2009) Increased retinopathy occurrence in type 1 diabetes patients with increased serum levels of the advanced glycation endproduct hydroimidazolone. Acta Ophthalmol. 87, 498-500
130. Fosmark, D.S., Torjesen, P.A., Kilhovd, B.K., Berg, T.J., Sandvik, L., Hanssen, K.F., Agardh, C.-D. D. and Agardh, E. (2006) Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism: Clin. Exp. 55, 232-236
131. Karachalias, N., Babaei-Jadidi, R., Ahmed, N. and Thornalley, P.J. (2003) Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem. Soc. Trans. 31, 1423-1425
132. Padayatti, P.S., Jiang, C., Glomb, M.A., Uchida, K. and Nagaraj, R.H. (2001) High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells. Curr. Eye Res. 23, 106-115
133. Bento, C.F., Fernandes, R., Matafome, P., Sena, C., Seiça, R. and Pereira, P. (2010) Methylglyoxal-induced imbalance in the ratio of vascular endothelial growth factor to angiopoietin 2 secreted by retinal pigment epithelial cells leads to endothelial dysfunction. Exp. Physiol. 95, 955-970
134. Liu, B., Bhat, M., Padival, A.K., Smith, D.G. and Nagaraj, R.H. (2004) Effect of dicarbonyl modification of fibronectin on retinal capillary pericytes. Invest. Ophthalmol. Vis. Sci. 45, 1983-1995
135. Miller, A.G., Smith, D.G., Bhat, M. and Nagaraj, R.H. (2006) Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions. J. Biol. Chem. 281, 11864-11871
136. Berner, A.K., Brouwers, O., Pringle, R., Klaassen, I., Colhoun, L., McVicar, C., Brockbank, S., Curry, J.W., Miyata, T., Brownlee, M. et al. (2012) Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 55, 845-854
137. Wang, J., Lin, J., Schlotterer, A., Wu, L., Fleming, T., Busch, S., Dietrich, N. and Hammes, H.P. (2014) CD74 indicates microglial activation in experimental diabetic retinopathy and exogenous methylglyoxal mimics the response in normoglycemic retina. Acta Diabetol. 51, 813-821
138. Wang, Y.H., Han, Y.P., Yu, H.T., Pu, X.P. and Du, G.H. (2014) Protocatechualdehyde prevents methylglyoxal-induced mitochondrial dysfunction and AGEs-RAGE axis activation in human lens epithelial cells. Eur. J. Pharmacol. 738, 374-383
139. Kim, J., Kim, N.H., Sohn, E., Kim, C.S. and Kim, J.S. (2010) Methylglyoxal induces cellular damage by increasing argpyrimidine accumulation and oxidative DNA damage in human lens epithelial cells. Biochem. Biophys. Res. Commun. 391, 346-351
140. Kim, J., Kim, O.S., Kim, C.S., Sohn, E., Jo, K. and Kim, J.S. (2012) Accumulation of argpyrimidine, a methylglyoxal-derived advanced glycation end product, increases apoptosis of lens epithelial cells both in vitro and in vivo. Exp. Mol. Med. 44, 167-175
141. Sugimoto, K., Yasujima, M. and Yagihashi, S. (2008) Role of advanced glycation end products in diabetic neuropathy. Curr. Pharm. Des. 14, 953-961
142. Bierhaus, A., Fleming, T., Stoyanov, S., Leffler, A., Babes, A., Neacsu, C., Sauer, S.K., Eberhardt, M., Schnölzer, M., Lasitschka, F. et al. (2012) Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat. Med. 18, 926-933
143. Genuth, S., Sun, W., Cleary, P., Gao, X., Sell, D.R., Lachin, J. and Monnier, V.M. (2015) Skin advanced glycation endproducts (AGEs) glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes 64, 266-278
144. Fukunaga, M., Miyata, S., Liu, B.F., Miyazaki, H., Hirota, Y., Higo, S., Hamada, Y., Ueyama, S. and Kasuga, M. (2004) Methylglyoxal induces apoptosis through activation of p38 MAPK in rat Schwann cells. Biochem. Biophys. Res. Commun. 320, 689-695
145. Lee, H.K., Seo, I.A., Suh, D.J., Lee, H.J. and Park, H.T. (2009) A novel mechanism of methylglyoxal cytotoxicity in neuroglial cells. J. Neurochem. 108, 273-284
146. Ohkawara, S., Tanaka-Kagawa, T., Furukawa, Y. and Jinno, H. (2012) Methylglyoxal activates the human transient receptor potential ankyrin 1 channel. J. Toxicol. Sci. 37, 831-835
147. Andersson, D.A., Gentry, C., Light, E., Vastani, N., Vallortigara, J., Bierhaus, A., Fleming, T. and Bevan, S. (2013) Methylglyoxal evokes pain by stimulating TRPA1. PloS ONE 8, e77986
148. Koivisto, A., Hukkanen, M., Saarnilehto, M., Chapman, H., Kuokkanen, K., Wei, H., Viisanen, H., Akerman, K.E., Lindstedt, K. and Pertovaara, A. (2012) Inhibiting TRPA1 ion channel reduces loss of cutaneous nerve fiber function in diabetic animals: sustained activation of the TRPA1 channel contributes to the pathogenesis of peripheral diabetic neuropathy. Pharmacol. Res. 65, 149-158
149. Eberhardt, M.J., Filipovic, M.R., Leffler, A., de la Roche, J., Kistner, K., Fischer, M.J., Fleming, T., Zimmermann, K., Ivanovic-Burmazovic, I., Nawroth, P.P. et al. (2012) Methylglyoxal activates nociceptors through transient receptor potential channel A1 (TRPA1): a possible mechanism of metabolic neuropathies. J. Biol. Chem. 287, 28291-28306
150. Jack, M. and Wright, D. (2012) Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Transl. Res. 159, 355-365
151. Grundy, S.M., Benjamin, I.J., Burke, G.L., Chait, A., Eckel, R.H., Howard, B.V., Mitch, W., Jr, Smith, S.C. and Sowers, J.R. (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100, 1134-1146
152. Ross, R. (1999) Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126
153. Virmani, R., Burke, A.P., Farb, A. and Kolodgie, F.D. (2006) Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 47, C13-C18
154. Rudd, J.H., Warburton, E.A., Fryer, T.D., Jones, H.A., Clark, J.C., Antoun, N., Johnstrom, P., Davenport, A.P., Kirkpatrick, P.J., Arch, B.N. et al. (2002) Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105, 2708-2711
155. Basta, G., Schmidt, A.M. and De Caterina, R. (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 63, 582-592
156. Kume, S., Takeya, M., Mori, T., Araki, N., Suzuki, H., Horiuchi, S., Kodama, T., Miyauchi, Y. and Takahashi, K. (1995) Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am. J. Pathol. 147, 654-667
157. Baidoshvili, A., Niessen, H.W., Stooker, W., Huybregts, R.A., Hack, C.E., Rauwerda, J.A., Meijer, C.J., Eijsman, L., van Hinsbergh, V.W. and Schalkwijk, C.G. (2004) N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. Atherosclerosis 174, 287-292
158. Tikellis, C., Pickering, R.J., Tsorotes, D., Huet, O., Cooper, M.E., Jandeleit-Dahm, K. and Thomas, M.C. (2014) Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. Diabetes 63, 3915-3925
159. Ogawa, S., Nakayama, K., Nakayama, M., Mori, T., Matsushima, M., Okamura, M., Senda, M., Nako, K., Miyata, T. and Ito, S. (2010) Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension 56, 471-476
160. Schalkwijk, C.G., Vermeer, M.A., Stehouwer, C.D., te Koppele, J., Princen, H.M. and van Hinsbergh, V.W. (1998) Effect of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein. Biochim. Biophys. Acta 1394, 187-198
161. Rabbani, N., Godfrey, L., Xue, M., Shaheen, F., Geoffrion, M., Milne, R. and Thornalley, P.J. (2011) Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 60, 1973-1980
162. Turk, Z., Cavlovic-Naglic, M. and Turk, N. (2011) Relationship of methylglyoxal-adduct biogenesis to LDL and triglyceride levels in diabetics. Life Sci. 89, 485-490
163. Brown, B.E., Dean, R.T. and Davies, M.J. (2005) Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells. Diabetologia 48, 361-369
164. Rabbani, N., Chittari, M.V., Bodmer, C.W., Zehnder, D., Ceriello, A. and Thornalley, P.J. (2010) Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 59, 1038-1045
165. Rye, K.A., Bursill, C.A., Lambert, G., Tabet, F. and Barter, P.J. (2009) The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50 (Suppl), S195-S200
166. Godfrey, L., Yamada-Fowler, N., Smith, J., Thornalley, P.J. and Rabbani, N. (2014) Arginine-directed glycation and decreased HDL plasma concentration and functionality. Nutr. Diabetes 4, e134
167. Bacchetti, T., Masciangelo, S., Armeni, T., Bicchiega, V. and Ferretti, G. (2014) Glycation of human high density lipoprotein by methylglyoxal: effect on HDL-paraoxonase activity. Metabolism: Clin. Exp. 63, 307-311
168. Cantero, A.V., Portero-Otin, M., Ayala, V., Auge, N., Sanson, M., Elbaz, M., Thiers, J.C., Pamplona, R., Salvayre, R. and Negre-Salvayre, A. (2007) Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis. FASEB J. 21, 3096-3106
169. Hanssen, N.M., Brouwers, O., Gijbels, M.J., Wouters, K., Wijnands, E., Cleutjens, J.P., De Mey, J.G., Miyata, T., Biessen, E.A., Stehouwer, C.D. et al. (2014) Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE-/- mice with or without diabetes. Cardiovasc. Res. 104, 160-170
170. Thangarajah, H., Yao, D., Chang, E.I., Shi, Y., Jazayeri, L., Vial, I.N., Galiano, R.D., Du, X.L., Grogan, R., Galvez, M.G. et al. (2009) The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc. Natl. Acad. Sci. U.S.A. 106, 13505-13510
171. Ceradini, D.J., Yao, D., Grogan, R.H., Callaghan, M.J., Edelstein, D., Brownlee, M. and Gurtner, G.C. (2008) Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J. Biol. Chem. 283, 10930-10938
172. Shao, C.H., Capek, H.L., Patel, K.P., Wang, M., Tang, K., DeSouza, C., Nagai, R., Mayhan, W., Periasamy, M. and Bidasee, K.R. (2011) Carbonylation contributes to SERCA2a activity loss and diastolic dysfunction in a rat model of type 1 diabetes. Diabetes 60, 947-959
173. Brouwers, O., de Vos-Houben, J.M., Niessen, P.M., Miyata, T., van Nieuwenhoven, F., Janssen, B.J., Hageman, G., Stehouwer, C.D. and Schalkwijk, C.G. (2013) Mild oxidative damage in the diabetic rat heart is attenuated by glyoxalase-1 overexpression. Int. J. Mol. Sci. 14, 15724-15739
174. Haslam, D.W. and James, W.P. (2005) Obesity. Lancet 366, 1197-1209
175. Jia, X., Chang, T., Wilson, T.W. and Wu, L. (2012) Methylglyoxal mediates adipocyte proliferation by increasing phosphorylation of Akt1. PLoS ONE 7, e36610
176. Rodrigues, L., Matafome, P., Crisostomo, J., Santos-Silva, D., Sena, C., Pereira, P. and Seica, R. (2014) Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation. J. Physiol. Biochem. 70, 173-184
177. Crisostomo, J., Matafome, P., Santos-Silva, D., Rodrigues, L., Sena, C.M., Pereira, P. and Seica, R. (2013) Methylglyoxal chronic administration promotes diabetes-like cardiac ischaemia disease in Wistar normal rats. Nutr. Metab. Cardiovasc. Dis. 23, 1223-1230
178. Rodrigues, T., Matafome, P., Santos-Silva, D., Sena, C. and Seica, R. (2013) Reduction of methylglyoxal-induced glycation by pyridoxamine improves adipose tissue microvascular lesions. J. Diabetes Res. 2013, 690650
179. Rodrigues, T., Matafome, P. and Seica, R. (2013) Methylglyoxal further impairs adipose tissue metabolism after partial decrease of blood supply. Arch. Physiol. Biochem. 119, 209-218
180. Kim, D.H., Joo, J.I., Choi, J.W. and Yun, J.W. (2010) Differential expression of skeletal muscle proteins in high-fat diet-fed rats in response to capsaicin feeding. Proteomics 10, 2870-2881
181. Schalkwijk, C.G., Brouwers, O. and Stehouwer, C.D. (2008) Modulation of insulin action by advanced glycation endproducts: a new player in the field. Horm. Metab. Res. 40, 614-619
182. Dhar, A., Dhar, I., Desai, K.M. and Wu, L. (2010) Methylglyoxal scavengers attenuate endothelial dysfunction induced by methylglyoxal and high concentrations of glucose. Br. J. Pharmacol. 161, 1843-1856
183. Jia, X. and Wu, L. (2007) Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats. Mol. Cell Biochem. 306, 133-139
184. Dhar, A., Dhar, I., Jiang, B., Desai, K.M. and Wu, L. (2011) Chronic methylglyoxal infusion by minipump causes pancreatic beta-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes 60, 899-908
185. Guo, Q., Mori, T., Jiang, Y., Hu, C., Osaki, Y., Yoneki, Y., Sun, Y., Hosoya, T., Kawamata, A., Ogawa, S. et al. (2009) Methylglyoxal contributes to the development of insulin resistance and salt sensitivity in Sprague-Dawley rats. J. Hypertens. 27, 1664-1671
186. Maessen, D.E.M., Scheijen, J.L.J.M., Gaens, K.H., Van Greevenbroek, M.M.J., Van der Kallen, C.J., Stehouwer, C.D. and Schalkwijk, C.G. (2014) Higher plasma concentrations of the methylglyoxal metabolite D-lactate are independently associated with insulin resistance: the CODAM study. J. Diabetes Metab. 5, 457, doi: 10.4172/2155-6156.1000457
187. Jia, X., Olson, D.J., Ross, A.R. and Wu, L. (2006) Structural and functional changes in human insulin induced by methylglyoxal. FASEB J. 20, 1555-1557
188. Riboulet-Chavey, A., Pierron, A., Durand, I., Murdaca, J., Giudicelli, J. and Van Obberghen, E. (2006) Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 55, 1289-1299
189. Fiory, F., Lombardi, A., Miele, C., Giudicelli, J., Beguinot, F. and Van Obberghen, E. (2011) Methylglyoxal impairs insulin signalling and insulin action on glucose-induced insulin secretion in the pancreatic beta cell line INS-1E. Diabetologia 54, 2941-2952
190. Nigro, C., Raciti, G.A., Leone, A., Fleming, T.H., Longo, M., Prevenzano, I., Fiory, F., Mirra, P., D'Esposito, V., Ulianich, L. et al. (2014) Methylglyoxal impairs endothelial insulin sensitivity both in vitro and in vivo. Diabetologia 57, 1485-1494
191. Deichen, J.T., Prante, O., Gack, M., Schmiedehausen, K. and Kuwert, T. (2003) Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur. J. Nucl. Med. Mol. Imaging 30, 267-273
192. Schalkwijk, C.G., Vermeer, M.A., Stehouwer, C.D., te Koppele, J., Princen, H.M. and van Hinsbergh, V.W. (1998) Effect of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein. Biochim. Biophys. Acta 1394, 187-198
193. Wu, L. and Juurlink, B.H. (2002) Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39, 809-814
194. Wang, X., Desai, K., Clausen, J.T. and Wu, L. (2004) Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int. 66, 2315-2321
195. Wang, X., Desai, K., Chang, T. and Wu, L. (2005) Vascular methylglyoxal metabolism and the development of hypertension. J. Hypertens. 23, 1565-1573
196. Vasdev, S., Ford, C.A., Longerich, L., Parai, S., Gadag, V. and Wadhawan, S. (1998) Aldehyde induced hypertension in rats: prevention by N-acetyl cysteine. Artery 23, 10-36
197. Dhar, I., Dhar, A., Wu, L. and Desai, K.M. (2014) Methylglyoxal, a reactive glucose metabolite, increases renin angiotensin aldosterone and blood pressure in male Sprague-Dawley rats. Am. J. Hypertens. 27, 308-316
198. Guo, Q., Mori, T., Jiang, Y., Hu, C., Ohsaki, Y., Yoneki, Y., Nakamichi, T., Ogawa, S., Sato, H. and Ito, S. (2012) Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats. Hypertens. Res. 35, 48-54
199. Sanchez-Lozada, L.G., Tapia, E., Jimenez, A., Bautista, P., Cristobal, M., Nepomuceno, T., Soto, V., Avila-Casado, C., Nakagawa, T., Johnson, R.J. et al. (2007) Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am. J. Physiol. Renal Physiol. 292, F423-F429
200. Chen, X., Mori, T., Guo, Q., Hu, C., Ohsaki, Y., Yoneki, Y., Zhu, W., Jiang, Y., Endo, S., Nakayama, K. et al. (2013) Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. Hypertens. Res. 36, 361-367
201. Wang, X., Chang, T., Jiang, B., Desai, K. and Wu, L. (2007) Attenuation of hypertension development by aminoguanidine in spontaneously hypertensive rats: role of methylglyoxal. Am. J. Hypertens. 20, 629-636
202. Wang, X., Jia, X., Chang, T., Desai, K. and Wu, L. (2008) Attenuation of hypertension development by scavenging methylglyoxal in fructose-treated rats. J. Hypertens. 26, 765-772
203. International Agency for Research on Cancer. World Cancer Report 2014. Geneva: World Health Organization, 2014
204. Hosoda, F., Arai, Y., Okada, N., Shimizu, H., Miyamoto, M., Kitagawa, N., Katai, H., Taniguchi, H., Yanagihara, K., Imoto, I. et al. (2014) Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer. Oncogene, 1-11, doi: 10.1038/onc.2014.57
205. Antognelli, C., Mezzasoma, L., Fettucciari, K., Mearini, E. and Talesa, V.N. (2013) Role of glyoxalase I in the proliferation and apoptosis control of human LNCaP and PC3 prostate cancer cells. Prostate 73, 121-132
206. Loarca, L., Sassi-Gaha, S. and Artlett, C.M. (2013) Two alpha-dicarbonyls down-regulate migration, invasion, and adhesion of liver cancer cells in a p53-dependent manner. Dig. Liver Dis. 45, 938-946
207. Antognelli, C., Mezzasoma, L., Fettucciari, K. and Talesa, V.N. (2013) A novel mechanism of methylglyoxal cytotoxicity in prostate cancer cells. Int. J. Biochem. Cell Biol. 45, 836-844
208. van Heijst, J.W., Niessen, H.W., Musters, R.J., van Hinsbergh, V.W., Hoekman, K. and Schalkwijk, C.G. (2006) Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis. Cancer Lett. 241, 309-319
209. Ranganathan, S., Walsh, E.S. and Tew, K.D. (1995) Glyoxalase I in detoxification: studies using a glyoxalase I transfectant cell line. Biochem. J. 309 (Pt 1), 127-131
210. Thornalley, P.J., Edwards, L.G., Kang, Y., Wyatt, C., Davies, N., Ladan, M.J. and Double, J. (1996) Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochem. Pharmacol. 51, 1365-1372
211. Speer, O., Morkunaite-Haimi, S., Liobikas, J., Franck, M., Hensbo, L., Linder, M.D., Kinnunen, P.K., Wallimann, T. and Eriksson, O. (2003) Rapid suppression of mitochondrial permeability transition by methylglyoxal. Role of reversible arginine modification. J. Biol. Chem. 278, 34757-34763
212. Bartyik, K., Turi, S., Orosz, F. and Karg, E. (2004) Methotrexate inhibits the glyoxalase system in vivo in children with acute lymphoid leukaemia. Eur. J. Cancer 40, 2287-2292
213. Santel, T., Pflug, G., Hemdan, N.Y., Schafer, A., Hollenbach, M., Buchold, M., Hintersdorf, A., Lindner, I., Otto, A., Bigl, M. et al. (2008) Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. PloS ONE 3, e3508
214. Yuan, M., Luo, M., Song, Y., Xu, Q., Wang, X., Cao, Y., Bu, X., Ren, Y. and Hu, X. (2011) Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies. Bioorg. Med. Chem. 19, 1189-1196
215. Chen, F., Wollmer, M.A., Hoerndli, F., Munch, G., Kuhla, B., Rogaev, E.I., Tsolaki, M., Papassotiropoulos, A. and Gotz, J. (2004) Role for glyoxalase I in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101, 7687-7692
216. Beeri, M.S., Moshier, E., Schmeidler, J., Godbold, J., Uribarri, J., Reddy, S., Sano, M., Grossman, H.T., Cai, W., Vlassara, H. et al. (2011) Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech. Ageing Dev. 132, 583-587
217. Srikanth, V., Westcott, B., Forbes, J., Phan, T.G., Beare, R., Venn, A., Pearson, S., Greenaway, T., Parameswaran, V. and Munch, G. (2013) Methylglyoxal, cognitive function and cerebral atrophy in older people. J. Gerontol. A Biol. Sci. Med. Sci. 68, 68-73
218. Angeloni, C., Zambonin, L. and Hrelia, S. (2014) Role of methylglyoxal in Alzheimer's disease. Biomed. Res. Int. 2014, 238485
219. Ahmed, N., Ahmed, U., Thornalley, P.J., Hager, K., Fleischer, G. and Munch, G. (2005) Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J. Neurochem. 92, 255-263
220. Tajes, M., Eraso-Pichot, A., Rubio-Moscardo, F., Guivernau, B., Bosch-Morato, M., Valls-Comamala, V. and Munoz, F.J. (2014) Methylglyoxal reduces mitochondrial potential and activates Bax and caspase-3 in neurons: Implications for Alzheimer's disease. Neurosc. Lett. 580, 78-82
221. Cardoso, S., Carvalho, C., Marinho, R., Simoes, A., Sena, C.M., Matafome, P., Santos, M.S., Seica, R.M. and Moreira, P.I. (2014) Effects of methylglyoxal and pyridoxamine in rat brain mitochondria bioenergetics and oxidative status. J. Bioenerg. Biomembr. 46, 347-355
222. Markesbery, W.R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134-147
223. Lloret, A., Badia, M.C., Mora, N.J., Pallardo, F.V., Alonso, M.D. and Vina, J. (2009) Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J. Alzheimers Dis. 17, 143-149
224. Kuhla, B., Boeck, K., Schmidt, A., Ogunlade, V., Arendt, T., Munch, G. and Luth, H.J. (2007) Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. Neurobiol. Aging 28, 29-41
225. Auburger, G. and Kurz, A. (2011) The role of glyoxalases for sugar stress and aging, with relevance for dyskinesia, anxiety, dementia and Parkinson's disease. Aging (Albany, NY) 3, 5-9
226. Kurz, A., Rabbani, N., Walter, M., Bonin, M., Thornalley, P., Auburger, G. and Gispert, S. (2011) Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell. Mol. Life Sci. 68, 721-733
227. Hipkiss, A.R. (2014) Aging risk factors and Parkinson's disease: contrasting roles of common dietary constituents. Neurobiol. Aging 35, 1469-1472
228. Arai, M., Yuzawa, H., Nohara, I., Ohnishi, T., Obata, N., Iwayama, Y., Haga, S., Toyota, T., Ujike, H., Ichikawa, T. et al. (2010) Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch. Gen. Psychiatry 67, 589-597
229. Toyosima, M., Maekawa, M., Toyota, T., Iwayama, Y., Arai, M., Ichikawa, T., Miyashita, M., Arinami, T., Itokawa, M. and Yoshikawa, T. (2011) Schizophrenia with the 22q11.2 deletion and additional genetic defects: case history. Br. J. Psychiatry 199, 245-246
230. Kromer, S.A., Kessler, M.S., Milfay, D., Birg, I.N., Bunck, M., Czibere, L., Panhuysen, M., Putz, B., Deussing, J.M., Holsboer, F. et al. (2005) Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J. Neurosci. 25, 4375-4384
231. Hovatta, I., Tennant, R.S., Helton, R., Marr, R.A., Singer, O., Redwine, J.M., Ellison, J.A., Schadt, E.E., Verma, I.M., Lockhart, D.J. et al. (2005) Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 438, 662-666
232. Ditzen, C., Jastorff, A.M., Kessler, M.S., Bunck, M., Teplytska, L., Erhardt, A., Kromer, S.A., Varadarajulu, J., Targosz, B.S., Sayan-Ayata, E.F. et al. (2006) Protein biomarkers in a mouse model of extremes in trait anxiety. Mol. Cell Proteomics 5, 1914-1920
233. Williams, R.T., Lim, J.E., Harr, B., Wing, C., Walters, R., Distler, M.G., Teschke, M., Wu, C., Wiltshire, T., Su, A.I. et al. (2009) A common and unstable copy number variant is associated with differences in Glo1 expression and anxiety-like behavior. PloS ONE 4, e4649
234. Hambsch, B., Chen, B.G., Brenndorfer, J., Meyer, M., Avrabos, C., Maccarrone, G., Liu, R.H., Eder, M., Turck, C.W. and Landgraf, R. (2010) Methylglyoxal-mediated anxiolysis involves increased protein modification and elevated expression of glyoxalase 1 in the brain. J. Neurochem. 113, 1240-1251
235. Distler, M.G., Plant, L.D., Sokoloff, G., Hawk, A.J., Aneas, I., Wuenschell, G.E., Termini, J., Meredith, S.C., Nobrega, M.A. and Palmer, A.A. (2012) Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J. Clin. Invest. 122, 2306-2315
236. Poggioli, S., Bakala, H. and Friguet, B. (2002) Age-related increase of protein glycation in peripheral blood lymphocytes is restricted to preferential target proteins. Exp. Gerontol. 37, 1207-1215
237. Xue, M., Rabbani, N. and Thornalley, P.J. (2011) Glyoxalase in ageing. Semin. Cell Dev. Biol. 22, 293-301
238. Kirk, J.E. (1960) The glyoxalase I activity of arterial tissue in individuals of various ages. J. Gerontol. 15, 139-141
239. McLellan, A.C. and Thornalley, P.J. (1989) Glyoxalase activity in human red blood cells fractioned by age. Mech. Ageing Dev. 48, 63-71
240. Kuhla, B., Boeck, K., Luth, H.J., Schmidt, A., Weigle, B., Schmitz, M., Ogunlade, V., Munch, G. and Arendt, T. (2006) Age-dependent changes of glyoxalase I expression in human brain. Neurobiol. Aging 27, 815-822
241. Schlotterer, A., Kukudov, G., Bozorgmehr, F., Hutter, H., Du, X., Oikonomou, D., Ibrahim, Y., Pfisterer, F., Rabbani, N., Thornalley, P. et al. (2009) C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes 58, 2450-2456
242. Scheckhuber, C.Q., Mack, S.J., Strobel, I., Ricciardi, F., Gispert, S. and Osiewacz, H.D. (2010) Modulation of the glyoxalase system in the aging model Podospora anserina: effects on growth and lifespan. Aging (Albany NY) 2, 969-980
243. Ikeda, Y., Inagi, R., Miyata, T., Nagai, R., Arai, M., Miyashita, M., Itokawa, M., Fujita, T. and Nangaku, M. (2011) Glyoxalase I retards renal senescence. Am. J. Pathol. 179, 2810-2821
244. Haik, Jr, G.M., Lo, T.W. and Thornalley, P.J. (1994) Methylglyoxal concentration and glyoxalase activities in the human lens. Exp. Eye Res. 59, 497-500
245. Shamsi, F.A., Lin, K., Sady, C. and Nagaraj, R.H. (1998) Methylglyoxal-derived modifications in lens aging and cataract formation. Invest. Ophthalmol. Vis. Sci. 39, 2355-2364
246. Mailankot, M., Padmanabha, S., Pasupuleti, N., Major, D., Howell, S. and Nagaraj, R.H. (2009) Glyoxalase I activity and immunoreactivity in the aging human lens. Biogerontology 10, 711-720
247. Fan, X., Sell, D.R., Zhang, J., Nemet, I., Theves, M., Lu, J., Strauch, C., Halushka, M.K. and Monnier, V.M. (2010) Anaerobic vs aerobic pathways of carbonyl and oxidant stress in human lens and skin during aging and in diabetes: A comparative analysis. Free Radic. Biol. Med. 49, 847-856
248. Jo-Watanabe, A., Ohse, T., Nishimatsu, H., Takahashi, M., Ikeda, Y., Wada, T., Shirakawa, J., Nagai, R., Miyata, T., Nagano, T. et al. (2014) Glyoxalase I reduces glycative and oxidative stress and prevents age-related endothelial dysfunction through modulation of endothelial nitric oxide synthase phosphorylation. Aging Cell 13, 519-528
249. Fleming, T.H., Theilen, T.M., Masania, J., Wunderle, M., Karimi, J., Vittas, S., Bernauer, R., Bierhaus, A., Rabbani, N., Thornalley, P.J. et al. (2013) Aging-dependent reduction in glyoxalase 1 delays wound healing. Gerontology 59, 427-437
250. Verma, M. and Srivastava, S. (2002) Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. 3, 755-763
251. El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P.L., Roeder, R.G., Cooper, M.E. and Brownlee, M. (2008) Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205, 2409-2417
252. Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P. and Cerami, A. (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232, 1629-1632
253. Lo, T.W., Selwood, T. and Thornalley, P.J. (1994) The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem. Pharmacol. 48, 1865-1870
254. Soulis-Liparota, T., Cooper, M., Papazoglou, D., Clarke, B. and Jerums, G. (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40, 1328-1334
255. Soulis, T., Cooper, M.E., Vranes, D., Bucala, R. and Jerums, G. (1996) Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int. 50, 627-634
256. Hammes, H.P., Martin, S., Federlin, K., Geisen, K. and Brownlee, M. (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. U.S.A. 88, 11555-11558
257. Kihara, M., Schmelzer, J.D., Poduslo, J.F., Curran, G.L., Nickander, K.K. and Low, P.A. (1991) Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc. Natl. Acad. Sci. U.S.A. 88, 6107-6111
258. Bolton, W.K., Cattran, D.C., Williams, M.E., Adler, S.G., Appel, G.B., Cartwright, K., Foiles, P.G., Freedman, B.I., Raskin, P., Ratner, R.E. et al. (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24, 32-40
259. Freedman, B.I., Wuerth, J.P., Cartwright, K., Bain, R.P., Dippe, S., Hershon, K., Mooradian, A.D. and Spinowitz, B.S. (1999) Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin. Trials 20, 493-510
260. Vasan, S., Foiles, P. and Founds, H. (2003) Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch. Biochem. Biophys. 419, 89-96
261. Sell, D.R. and Monnier, V.M. (2012) Molecular basis of arterial stiffening: role of glycation - a mini-review. Gerontology 58, 227-237
262. Engelen, L., Stehouwer, C.D. and Schalkwijk, C.G. (2013) Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes. Metab. 15, 677-689
263. Kass, D.A., Shapiro, E.P., Kawaguchi, M., Capriotti, A.R., Scuteri, A., deGroof, R.C. and Lakatta, E.G. (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104, 1464-1470
264. Hartog, J.W., Willemsen, S., van Veldhuisen, D.J., Posma, J.L., van Wijk, L.M., Hummel, Y.M., Hillege, H.L. and Voors, A.A. (2011) Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur. J. Heart Fail. 13, 899-908
265. Zieman, S.J., Melenovsky, V., Clattenburg, L., Corretti, M.C., Capriotti, A., Gerstenblith, G. and Kass, D.A. (2007) Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J. Hypertens. 25, 577-583
266. Little, W.C., Zile, M.R., Kitzman, D.W., Hundley, W.G., O'Brien, T.X. and Degroof, R.C. (2005) The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J. Card. Fail. 11, 191-195
267. Viollet, B., Guigas, B., Sanz Garcia, N., Leclerc, J., Foretz, M. and Andreelli, F. (2012) Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond.) 122, 253-270
268. Giannarelli, R., Aragona, M., Coppelli, A. and Del Prato, S. (2003) Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 29, 6S28-35
269. Madiraju, A.K., Erion, D.M., Rahimi, Y., Zhang, X.M., Braddock, D.T., Albright, R.A., Prigaro, B.J., Wood, J.L., Bhanot, S., MacDonald, M.J. et al. (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542-546
270. Ruggiero-Lopez, D., Lecomte, M., Moinet, G., Patereau, G., Lagarde, M. and Wiernsperger, N. (1999) Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol. 58, 1765-1773
271. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865
272. Kender, Z., Fleming, T., Kopf, S., Torzsa, P., Grolmusz, V., Herzig, S., Schleicher, E., Racz, K., Reismann, P. and Nawroth, P.P. (2014) Effect of metformin on methylglyoxal metabolism in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 122, 316-319
273. Battah, S.A.N. and Thornalley, PJ. (2002) Kinetics and mechanism of the reaction of metformin with methylglyoxal. Int. Congress Series 1245, 355-356
274. Voziyan, P.A. and Hudson, B.G. (2005) Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell. Mol. Life Sci. 62, 1671-1681
275. Degenhardt, T.P., Alderson, N.L., Arrington, D.D., Beattie, R.J., Basgen, J.M., Steffes, M.W., Thorpe, S.R. and Baynes, J.W. (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61, 939-950
276. Zhu, P., Lin, H., Sun, C., Lin, F., Yu, H., Zhuo, X., Zhou, C. and Deng, Z. (2012) Synergistic effects of telmisartan and pyridoxamine on early renal damage in spontaneously hypertensive rats. Mol. Med. Rep. 5, 655-662
277. Waanders, F., van den Berg, E., Nagai, R., van Veen, I., Navis, G. and van Goor, H. (2008) Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats. Nephrol. Dia.l Transplant. 23, 518-524
278. Alderson, N.L., Chachich, M.E., Youssef, N.N., Beattie, R.J., Nachtigal, M., Thorpe, S.R. and Baynes, J.W. (2003) The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int. 63, 2123-2133
279. Tanimoto, M., Gohda, T., Kaneko, S., Hagiwara, S., Murakoshi, M., Aoki, T., Yamada, K., Ito, T., Matsumoto, M., Horikoshi, S. et al. (2007) Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism: Clin. Exp. 56, 160-167
280. Williams, M.E., Bolton, W.K., Khalifah, R.G., Degenhardt, T.P., Schotzinger, R.J. and McGill, J.B. (2007) Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol. 27, 605-614
281. Lewis, E.J., Greene, T., Spitalewiz, S., Blumenthal, S., Berl, T., Hunsicker, L.G., Pohl, M.A., Rohde, R.D., Raz, I., Yerushalmy, Y. et al. (2012) Pyridorin in type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 23, 131-136
282. Garg, S., Syngle, A. and Vohra, K. (2013) Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study. Clin. J. Pain. 29, 717-724
283. Hammes, H.P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D. et al. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9, 294-299
284. Miller, A.G., Tan, G., Binger, K.J., Pickering, R.J., Thomas, M.C., Nagaraj, R.H., Cooper, M.E. and Wilkinson-Berka, J.L. (2010) Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 59, 3208-3215
285. Nagaraj, R.H., Sarkar, P., Mally, A., Biemel, K.M., Lederer, M.O. and Padayatti, P.S. (2002) Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch. Biochem. Biophys. 402, 110-119
286. Cheng, A.S., Cheng, Y.H., Chiou, C.H. and Chang, T.L. (2012) Resveratrol upregulates Nrf2 expression to attenuate methylglyoxal-induced insulin resistance in Hep G2 cells. J. Agric. Food Chem. 60, 9180-9187
287. Maher, P., Dargusch, R., Ehren, J.L., Okada, S., Sharma, K. and Schubert, D. (2011) Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes. PloS ONE 6, e21226
288. Xue, M., Rabbani, N., Momiji, H., Imbasi, P., Anwar, M.M., Kitteringham, N., Park, B.K., Souma, T., Moriguchi, T., Yamamoto, M. et al. (2012) Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem. J. 443, 213-222
289. Das, B.N., Kim, Y.W. and Keum, Y.S. (2013) Mechanisms of Nrf2/Keap1-dependent phase II cytoprotective and detoxifying gene expression and potential cellular targets of chemopreventive isothiocyanates. Oxid. Med. Cell Longev. 2013, 839409
290. Mann, G.E., Niehueser-Saran, J., Watson, A., Gao, L., Ishii, T., de Winter, P. and Siow, R.C. (2007) Nrf2/ARE regulated antioxidant gene expression in endothelial and smooth muscle cells in oxidative stress: implications for atherosclerosis and preeclampsia. Sheng Li Xue Bao 59, 117-127
291. Hsu, W.H., Lee, B.H., Chang, Y.Y., Hsu, Y.W. and Pan, T.M. (2013) A novel natural Nrf2 activator with PPARgamma-agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia. Toxicol. Appl. Pharmacol. 272, 842-851
292. Impellizzeri, D., Esposito, E., Attley, J. and Cuzzocrea, S. (2014) Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). Pharmacol. Res. 81, 91-102
293. McCullough, P.A. and Ali, S. (2012) Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl. Drug Des. Devel. Ther. 6, 141-149
294. Thomas, M. (2012) A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy. Expert Opin. Drug Metab. Toxicol. 8, 1015-1022
295. Thomas, M.C. (2011) Bardoxolone: augmenting the Yin in chronic kidney disease. Diab. Vasc. Dis. Res. 8, 303-304